Deferasirox effect on renal haemodynamic parameters in patients with transfusion‐dependent β thalassaemia
Open Access
- 17 November 2014
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 168 (6), 882-890
- https://doi.org/10.1111/bjh.13217
Abstract
Some patients with β thalassaemia experience non‐progressive creatinine increases with deferasirox, mostly within normal limits; the mechanisms involved are not fully elucidated. The effects of deferasirox on renal haemodynamics, including glomerular filtration rate (GFR) and renal plasma flow (RPF), were investigated in a Phase I, open‐label study in β thalassaemia major patients with iron overload. Patients received deferasirox 30 mg/kg/d up to Week 8, followed by a 2‐week washout period, and extended treatment up to Week 104 with a 4‐week washout period. In the short‐term study (n = 11), mean GFR and RPF declined from baseline to Week 8 (mean [%] change:−9·2 [−9·5%] and −105·7 ml/min [−17·8%], respectively). A similar pattern was observed during the long‐term study (n = 5); mean GFR and RPF decreased up to Week 52 (−19·1 [−17·7%] and −155·6 ml/min [−26·1%]), with similar change at Week 104 (−18·4 [−17·2%] and −115·9 ml/min [−19·6%]). Measures returned to baseline values after each washout. Serum creatinine and creatinine clearance followed a similar pattern. Effects of deferasirox on renal haemodynamics were mild and reversible for up to 2 years of treatment, with no progressive worsening of renal function over time. www.clinicaltrials.gov: NCT00560820.Keywords
Funding Information
- Novartis
This publication has 25 references indexed in Scilit:
- Renal aspects of thalassaemia a changing paradigmEuropean Journal of Haematology, 2012
- Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-upBlood, 2011
- Renal function in transfusion-dependent pediatric beta-thalassemia major patientsHematology, 2011
- Renal Dysfunction in Patients with Beta-Thalassemia Major Receiving Iron Chelation Therapy either with Deferoxamine and Deferiprone or with DeferasiroxActa Haematologica, 2010
- Renal Functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective studyItalian Journal of Pediatrics, 2010
- Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemiasHaematologica, 2009
- A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemiaBlood, 2006
- Guidelines for the measurement of glomerular filtration rate using plasma samplingNuclear Medicine Communications, 2004
- How to prevent, recognize, and treat drug-induced nephrotoxicity.Cleveland Clinic Journal of Medicine, 2002
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976